Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03413124 · ClinicalTrials.gov registry record · Phase 1
Bioavailability Study of MGL-3196 Tablets Compared to Capsules
A Phase 1 study, sponsored by Madrigal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03413124 is a Phase 1 study that has completed, run by Madrigal Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT03413124, a Phase 1 study, has completed, sponsored by Madrigal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the pharmacokinetics of MGL-3196 capsules with MGL-3196 tablets in healthy male subjects and female subjects not of child-bearing potential.
Interventions
- DRUG MGL-3196 Tablet
- DRUG MGL-3196 Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-02-05 |
| Est. Completion | 2018-03-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03413124
The ClinicalTrials.gov registry entry for NCT03413124 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Madrigal Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MGL-3196 Tablet is the first listed.
NCT03413124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03413124 about?
NCT03413124 is a clinical study titled "Bioavailability Study of MGL-3196 Tablets Compared to Capsules". The purpose of this study is to compare the pharmacokinetics of MGL-3196 capsules with MGL-3196 tablets in healthy male subjects and female subjects not of child-bearing potential.
What is the current status of trial NCT03413124?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-02-05. Estimated completion is 2018-03-13.
What interventions are being tested in trial NCT03413124?
The interventions under investigation include: MGL-3196 Tablet (DRUG), MGL-3196 Capsule (DRUG).
Who is sponsoring clinical trial NCT03413124?
This trial is sponsored by Madrigal Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.